The Clinical Impact of Hexylaminolevulinate-Blue Light
Cystoscopy on Non-Muscle Invasive Bladder Cancer
(NMIBC) Recurrence and Progression: A Critical Review
Volume 1 - Issue 4
Omer Abdalla1,2,3*, Seshadri Sriprasad1,2 and Sanjeev Madaan1,2
-
Author Information
Open or Close
- 1Dartford and Gravesham NHS Foundation Trust
- 2Canterbury Christ Church University
- 3Portsmouth Hospitals NHS Foundation Trust
*Corresponding author:
Omer Abdalla, Dartford and Gravesham NHS Foundation Trust, Canterbury Christ Church University,
Portsmouth Hospitals NHS Foundation Trust, UK
Received: May 14, 2019; Published: May 22, 2019
DOI: 10.32474/JUNS.2019.01.000123
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
The superficial bladder cancer is associated with high risk of recurrence and progression, necessitating lengthy follow up
and repeated endoscopic treatments. White light cystoscopy (WLC) is the current gold standard for the diagnosis, treatment and
surveillance, however the sensitivity and specificity isn’t perfect with risk of missing some tumours. A photodynamic diagnosis
(PDD) using Blue-light cystoscopy is a novel concept proposed to overcome the WLC shortcomings. This critical review synthesizes
the evidences on the effectiveness of Blue light cystoscopy (BLC) for the diagnosis of non-muscle invasive bladder cancer (NMIBC),
and the impact of photodynamic diagnosis on the recurrence rate and progression of superficial bladder cancer..
Abstract|
Introduction|
Methodology|
Conclusion|
References|